Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.51 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.42 |
| ▸ | GRM5 | P41594 | 7/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3120011 | 0.88 | CNR1 (0.54) | CNR1PDK4JAK1CDK7CDK13 | |
| SCHEMBL6870916 | 0.87 | CCR1 (0.41) | CNR1PDK4 | |
| SCHEMBL19701841 | 0.83 | CNR1 (0.55) | CNR1PDK4JAK1NAMPTHTR6 | |
| SCHEMBL4888709 | 0.83 | CNR1 (0.53) | CNR1PDK4JAK1NAMPTHTR6 | |
| SCHEMBL27598379 | 0.82 | CNR1 (0.49) | CNR1PDK4JAK1CDK7CDK13 | |
| SCHEMBL27598382 | 0.82 | CNR1 (0.49) | CNR1PDK4JAK1CDK7CDK13 | |
| SCHEMBL4825697 | 0.81 | CNR1 (0.54) | CNR1PDK4JAK1NAMPTHTR6 | |
| SCHEMBL4321326 | 0.81 | CNR1 (0.55) | CNR1PDK4JAK1NAMPTHTR6 | |
| SCHEMBL31342210 | 0.80 | CNR1 (0.55) | CNR1PDK4JAK1NAMPTHTR6 | |
| SCHEMBL15556190 | 0.80 | CNR1 (0.55) | CNR1PDK4JAK1NAMPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383501-B1 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1383501-A4 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20040266821-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | UJJAINWALLA FEROZE | 2004-12-30 | — | — | US | disclosed |
| US-6818658-B2 | TREATING OBESITY, DIABETES, SEXUAL DYSFUNCTION, INCLUDING ERECTILE DYSFUNCTION AND FEMALE SEXUAL DYSFUNCTION. | MERCK & CO., INC. | 2004-11-16 | — | — | US | disclosed |
| EP-1383501-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030225060-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2003-12-04 | — | — | US | disclosed |
| WO-2002068388-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225060-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | CNR1 229/4885PDK4 1273/4885JAK1 3441/4885 |
| US-20040266821-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | CNR1 229/4885PDK4 1273/4885JAK1 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.